Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | ACACA | Q13085 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412702 | 0.91 | MAPK1 (0.54) | L3MBTL3L3MBTL1ATRLRRK2ADORA2A | |
| SCHEMBL5405500 | 0.91 | ADORA1 (0.47) | L3MBTL3L3MBTL1ATRACACBACACA | |
| SCHEMBL5407380 | 0.90 | MAPK1 (0.48) | ADORA2AADORA1MAPK1MAPK10 | |
| SCHEMBL5396033 | 0.89 | ADORA1 (0.46) | ATRLMNAADORA2AADORA1MAPK1 | |
| SCHEMBL5396939 | 0.86 | LRRK2 (0.44) | L3MBTL3L3MBTL1ATRLRRK2MAPK1 | |
| SCHEMBL5407179 | 0.86 | ADORA1 (0.47) | ACACBACACAADORA2AADORA1 | |
| SCHEMBL5401255 | 0.83 | MAPK1 (0.51) | ATRADORA2AADORA1MAPK1 | |
| SCHEMBL5395571 | 0.83 | ALOX5AP (0.43) | ATRADORA2AADORA1MAPK1MAPK10 | |
| SCHEMBL5392519 | 0.82 | TACR3 (0.48) | ADORA2AADORA1 | |
| SCHEMBL5402140 | 0.82 | HRH4 (0.46) | ATRADORA2AADORA1MAPK1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | L3MBTL3 2148/4885L3MBTL1 1804/4885ATR 3064/4885 |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | L3MBTL3 1555/4885L3MBTL1 1286/4885ATR 1039/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | L3MBTL3 1555/4885L3MBTL1 1286/4885ATR 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.